Legend Biotech News

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jul 17 07:36 ET

Legend Biotech | 6-K: Legend Biotech Announces Positive Overall Survival in CARTITUDE-4 Phase 3 Trial

Jul 2 08:04 ET

Legend Biotech | 6-K: Legend Biotech Announced Results for the First Time from the Phase 2 CARTITUDE-2 Cohort D Study in Multiple Myeloma Patients

Jun 3 16:09 ET

Legend Biotech | 6-K: Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 23 17:01 ET

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

Apr 22 13:11 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 16 07:34 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 8 07:07 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 29 08:02 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 15 15:21 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 13 08:38 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Feb 23 07:19 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jan 23 00:00 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jan 23 00:00 ET

Legend Biotech | 6-K: Legendary Biotech Releases Updated Company Profile

Jan 9 00:00 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 21, 2023 17:17 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 21, 2023 16:15 ET

Legend Biotech | 6-K: Legend Biotech Announces Presentation at the American Society of Hematology (ASH) 2023

Dec 11, 2023 19:32 ET

Legend Biotech | 6-K: Legend Biotech Announces Exclusive Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Nov 13, 2023 08:30 ET

Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Oct 17, 2023 08:00 ET

Legend Biotech | 6-K: Poll Results of 2023 Annual Meeting of Shareholders

Sep 25, 2023 08:00 ET